Overview
Trident Lifeline Limited is a rapidly growing pharmaceutical company, specializing in manufacturing and exporting pharmaceutical formulations globally. It operates in several regions, including Africa, Latin America, and Asia.
The company has shown robust financial growth, with a 44% year-over-year revenue increase in Q3FY26. Its EBITDA also surged by 53% in the same period, demonstrating a strong operational performance.
Strategic acquisitions have been pivotal for Trident, acquiring stakes in subsidiaries like TNS Pharma, TLL Parenterals, and Trident Mediquip, enhancing its manufacturing and distribution capabilities.
A hybrid manufacturing model is at the core of Trident's operations, combining in-house manufacturing with contract manufacturing to meet growing demands effectively.
Trident Lifeline is heavily investing in product registrations, with over 3,500 products in the pipeline, which could significantly propel its market presence and revenue growth in the coming years.
- Sector
Pharmaceuticals
- Industry
Pharmaceuticals - Indian - Bulk Drugs & Formln M/S
- Market Cap
320 Cr
- Volatility
Low Risk
- P/E Ratio
16.1
- Industry P/E
28.4
- PEG Ratio
0.3
- P/B Ratio
3.6
- 52W High
328.00
- 52W Low
237.00
Financial Ratios
Sales CAGR
- 1Y
- 94.85%
- 3Y
- 46.04%
- 5Y
- 68.88%
- 10Y
- —
Profit CAGR
- 1Y
- 76.60%
- 3Y
- 48.97%
- 5Y
- —
- 10Y
- —
ROE
- TTM
- 22.08%
- 3Y
- 15.92%
- 5Y
- 18.23%
- 10Y
- —
ROCE
- TTM
- 17.36%
- 3Y
- 20.80%
- 5Y
- 22.00%
- 10Y
- —
Technicals
Oscillators
Neutral
Bearish
0
Neutral
14
Bullish
0
Overall
Neutral
Bearish
0
Neutral
46
Bullish
0
Moving Averages
Neutral
Bearish
0
Neutral
32
Bullish
0
Peers
| Symbol | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
68.10 | 367 Cr | 52.35 | 1.28 | 0.00 | 2.62 | 6.18 | 1.50 | |
291.00 | 361 Cr | — | 2.24 | 0.00 | — | — | 0.00 | |
43.50 | 354 Cr | 30.45 | 5.29 | 0.00 | 16.97 | 20.65 | 8.44 | |
240.00 | 320 Cr | 24.23 | 3.39 | 0.77 | 12.57 | 13.83 | 7.53 | |
268.00 | 320 Cr | 16.49 | 3.55 | 0.00 | 22.08 | 17.36 | 7.60 | |
53.12 | 317 Cr | — | 1.00 | 0.00 | 1.60 | 1.50 | -1.02 | |
70.30 | 305 Cr | 31.13 | 0.94 | 0.00 | 22.69 | 25.33 | 9.70 |
Price Chart Comparison
Documents
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Actions
AI Mode
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Ask AI
